A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: A real and separate nosological entity?

Journal of the American Academy of Dermatology

Volumn 66, Issue 6, 2012, Pages 988-994

  Fortuna, Giulio ^a,b   Salas Alanis, Julio Cesar ^c   Guidetti, Eugenio ^d   Marinkovich, M Peter ^a,e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Medicina UANL   (Mexico)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

ADR; adverse drug reaction; CDR; challenge dechallenge rechallenge; CI; confidence interval; DIF; direct immunofluorescence; LABD; LAD; linear IgA bullous dermatosis; linear IgA disease; odds ratio; OR; vancomycin induced linear IgA disease; VILAD

Indexed keywords

CAPTOPRIL; COTRIMOXAZOLE; DICLOFENAC; IMMUNOGLOBULIN A; PHENYTOIN; VANCOMYCIN;

AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; CLINICAL FEATURE; DISEASE CLASSIFICATION; HUMAN; IMMUNOPATHOLOGY; LATENT PERIOD; LINEAR IMMUNOGLOBULIN A DISEASE; PRIORITY JOURNAL; REVIEW;

AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; FEMALE; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; SKIN DISEASES, VESICULOBULLOUS; VANCOMYCIN;

EID: 84861227725     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.09.018     Document Type: Review

References (58)

1. G. Fortuna, and M.P. Marinkovich Linear immunoglobulin A bullous dermatosis Clin Dermatol 30 2012 38 50
2. P.M. Collier, and F. Wojnarowska Drug-induced linear immunoglobulin A disease Clin Dermatol 11 1993 529 533
3. M. Camilleri, and J.L. Pace Drug-induced linear immunoglobulin-A bullous dermatosis Clin Dermatol 16 1998 389 391
4. C.A. Egan, and J.J. Zone Linear IgA bullous dermatosis Int J Dermatol 38 1999 818 827
5. S.V. Guide, and M.P. Marinkovich Linear IgA bullous dermatosis Clin Dermatol 19 2001 719 727
6. C.A. Naranjo, U. Busto, E.M. Sellers, P. Sandor, I. Ruiz, and E.A. Roberts A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 1981 239 245
7. T.O. Gabrielsen, F. Staerfelt, and P.O. Thune Drug-induced bullous dermatosis with linear IgA deposits along the basement membrane Acta Derm Venereol 61 1981 439 441
8. Z.B. Argenyi, W.F. Bergfeld, R. Valenzuela, J.T. McMahon, and J.S. Taylor Adult linear IgA disease associated with an erythema multiforme-like drug reaction Cleve Clin J Med 54 1987 445 450
9. J.D. McWhirter, K. Hashimoto, S. Fayne, and K. Ito Linear IgA bullous dermatosis related to lithium carbonate Arch Dermatol 123 1987 1120 1122
10. L.E. Klein, E. Shmunses, J.B. Carter, and M.Y. Walsh Linear IgA bullous dermatosis related to captopril treatment Cutis 44 1989 393 396
11. D. Petit, L. Borradori, M. Rybojad, and P. Morel Linear IgA bullous dermatosis after heart transplantation J Am Acad Dermatol 22 1990 851
12. E.J. Primka 3rd, M.O. Liranzo, W.F. Bergfeld, and J.W. Dijkstra Amiodarone-induced linear IgA disease J Am Acad Dermatol 31 1994 809 811
13. M.K. Kuechle, E. Stegemeir, B. Maynard, L.E. Gibson, K.M. Leiferman, and M.S. Peters Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature J Am Acad Dermatol 30 1994 187 192
14. A. Tranvan, D.S. Pezen, M. Medenica, G.C. Michelson, N. Vogelzang, and K.M. Soltani Interleukin-2 associated linear IgA bullous dermatosis J Am Acad Dermatol 35 1996 865 867
15. C. Paul, P. Wolkenstein, C. Prost, F. Caux, G. Rostoker, and M. Heller Drug-induced linear IgA disease: target antigens are heterogeneous Br J Dermatol 136 1997 406 411
16. I.S. Friedman, D. Rudikoff, R.G. Phelps, and A.N. Sapadin Captopril-triggered linear IgA bullous dermatosis Int J Dermatol 37 1998 608 612
17. S.H. Wakelin, J. Allen, S. Zhou, and F. Wojnarowska Drug-induced linear IgA disease with antibodies to collagen VII Br J Dermatol 138 1998 310 314
18. Y. Kano, T. Kokaji, and T. Shiohara Linear IgA bullous dermatosis in a patient with acute lymphocytic leukemia: possible involvement of granulocyte colony-stimulating factor Eur J Dermatol 9 1999 122 125
19. M.B. Bouldin, H.E. Clowers-Webb, J.L. Davis, M.T. McEvoy, and M.D. Davis Naproxen-associated linear IgA bullous dermatosis: case report and review Mayo Clin Proc 75 2000 967 970
20. J. del Pozo, W. Martinez, M.T. Yebra-Pimentel, M. Almagro, C. Pena-Penabad, and E. Fonseca Linear immunoglobulin A bullous dermatosis induced by gemcitabine Ann Pharmacother 35 2001 891 893
21. L.M. Cohen, and R.B. Ugent Linear IgA bullous dermatosis occurring after carbamazepine J Am Acad Dermatol 46 2002 S32 S33
22. O. Avci, M. Okmen, and S. Cetiner Acetaminophen-induced linear IgA bullous dermatosis J Am Acad Dermatol 48 2003 299 301
23. C. Pena-Penabad, J. Rodriguez-Lozano, J. del Pozo, J. Garcia-Silva, and E. Fonseca Linear IgA bullous dermatosis induced by angiotensin receptor antagonists Am J Med 114 2003 163 164
24. D. Tran, S. Kossard, and S. Shumack Phenytoin-induced linear IgA dermatosis mimicking toxic epidermal necrolysis Australas J Dermatol 44 2003 284 286
25. I. Shimanovich, C. Rose, C. Sitaru, E.B. Brocker, and D. Zillikens Localized linear IgA disease induced by ampicillin/sulbactam J Am Acad Dermatol 51 2004 95 98
26. J. Santos-Juanes, R. Coto Hernandez, L. Trapiella, L. Caminal, J. Sanchez del Rio, and J. Soto Amoxicillin-associated linear IgA bullous dermatosis J Eur Acad Dermatol Venereol 21 2007 992 993
27. J.E. Cummings, R.R. Snyder, E.B. Kelly, and S.S. Raimer Drug-induced linear immunoglobulin A bullous dermatosis mimicking Stevens-Johnson syndrome: a case report Cutis 79 2007 203 207
28. M. Polat, N. Lenk, E. Kurekci, P. Oztas, F. Artuz, and N. Alli Chronic bullous disease of childhood in a patient with acute lymphoblastic leukemia: possible induction by a drug Am J Clin Dermatol 8 2007 389 391
29. D. Kovacic, M. Fox, and J. Reichenberg Moxifloxacin as the likely cause of drug-induced linear immunoglobulin A bullous dermatosis J Drugs Dermatol 7 2008 794 795
30. I. Khan, R. Hughes, S. Curran, and P. Marren Drug-associated linear IgA disease mimicking toxic epidermal necrolysis Clin Exp Dermatol 34 2009 715 717
31. V. Panasiti, M. Rossi, V. Devirgiliis, M. Curzio, U. Bottoni, and S. Calvieri Amoxicillin-clavulanic acid-induced linear immunoglobulin A bullous dermatosis: case report and review of the literature Int J Dermatol 48 2009 1006 1010
32. P. Kocyigit, B.N. Akay, and N. Karaosmanoglu Linear IgA bullous dermatosis induced by interferon-alpha 2a Clin Exp Dermatol 34 2009 e123 e124
33. L.A. Baden, C. Apovian, M.J. Imber, and J.S. Dover Vancomycin-induced linear IgA bullous dermatosis Arch Dermatol 124 1988 1186 1188
34. S. Carpenter, D. Berg, N. Sidhu-Malik, R.P. Hall 3rd, and M.J. Rico Vancomycin-associated linear IgA dermatosis. A report of three cases J Am Acad Dermatol 26 1992 45 48
35. C. Piketty, F. Meeus, D. Nochy, J.M. Poux, C. Jacquot, and J. Bariety Linear IgA dermatosis related to vancomycin Br J Dermatol 130 1994 130 131
36. C. Geissmann, M. Beylot-Barry, M.S. Doutre, and C. Beylot Drug-induced linear IgA bullous dermatosis J Am Acad Dermatol 32 1995 296
37. L.M. Bitman, M.E. Grossman, and H. Ross Bullous drug eruption treated with amputation. A challenging case of vancomycin-induced linear IgA disease Arch Dermatol 132 1996 1289 1290
38. E.F. Bernstein, and M. Schuster Linear IgA bullous dermatosis associated with vancomycin Ann Intern Med 129 1998 508 509
39. H.C. Nousari, C. Costarangos, and G.J. Anhalt Vancomycin-associated linear IgA bullous dermatosis Ann Intern Med 129 1998 507 508
40. H.C. Nousari, A. Kimyai-Asadi, J.P. Caeiro, and G.J. Anhalt Clinical, demographic, and immunohistologic features of vancomycin-induced linear IgA bullous disease of the skin. Report of 2 cases and review of the literature Medicine (Baltimore) 78 1999 1 8
41. M.Z. Mofid, C. Costarangos, B. Bernstein, L. Wong, A. Munster, and H.C. Nousari Drug-induced linear immunoglobulin A bullous disease that clinically mimics toxic epidermal necrolysis J Burn Care Rehabil 21 2000 246 247
42. R. Ahkami, and I. Thomas Linear IgA bullous dermatosis associated with vancomycin and disseminated varicella-zoster infection Cutis 67 2001 423 426
43. T.P. Wiadrowski, and C.M. Reid Drug-induced linear IgA bullous disease following antibiotics Australas J Dermatol 42 2001 196 199
44. R.A. Palmer, G. Ogg, J. Allen, A. Banerjee, K.S. Ryatt, and R. Ratnavel Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285 Br J Dermatol 145 2001 816 820
45. R.P. Dellavalle, J.M. Burch, S. Tayal, L.E. Golitz, J.E. Fitzpatrick, and P. Walsh Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis J Am Acad Dermatol 48 2003 S56 S57
46. B.A. Solky, L. Pincus, and R.F. Horan Vancomycin-induced linear IgA bullous dermatosis: morphology is a key to diagnosis Cutis 73 2004 65 67
47. M.A. Waldman, D.R. Black, and J.P. Callen Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis Clin Exp Dermatol 29 2004 633 636
48. S. Joshi, G. Scott, and R.J. Looney A successful challenge in a patient with vancomycin-induced linear IgA dermatosis Ann Allergy Asthma Immunol 93 2004 101 103
49. S. Coelho, O. Tellechea, J.P. Reis, A. Mariano, and A. Figueiredo Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis Int J Dermatol 45 2006 995 996
50. K. Eisendle, H. Bonatti, N. Sepp, and R. Hopfl Vancomycin-induced linear IgA bullous dermatosis in an immunosuppressed transplant recipient J Eur Acad Dermatol Venereol 21 2007 996 997
51. H.C. McDonald, N.R. York, and A.G. Pandya Drug-induced linear IgA bullous dermatosis demonstrating the isomorphic phenomenon J Am Acad Dermatol 62 2010 897 898
52. Klein PA, Callen JP. Linear IgA dermatosis. Available from: http://emedicine.medscape.com/article/1063590-overview. Free access. Updated: Sep 28, 2010; accessed: May 31, 2011.
53. I.R. Edwards, and J.K. Aronson Adverse drug reactions: definitions, diagnosis, and management Lancet 356 2000 1255 1259
54. A. Farcas, and M. Bojita Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis J Gastrointestin Liver Dis 18 2009 353 358
55. W.N. Kelly The quality of published adverse drug event reports Ann Pharmacother 37 2003 1774 1778
56. T.B. Agbabiaka, J. Savović, and E. Ernst Methods for causality assessment of adverse drug reactions: a systematic review Drug Saf 31 2008 21 37
57. The use of the WHO-UMC system for standardised case causality assessment. Available from: http://who-umc.org/Graphics/24734.pdf. Accessed May 31, 2011.
58. W.N. Kelly, F.M. Arellano, J. Barnes, U. Bergman, I.R. Edwards, and A.M. Fernandez Guidelines for submitting adverse event reports for publication Pharmacoepidemiol Drug Saf 16 2007 581 587